Benitec Biopharma Inc.
BNTC
$12.37
-$0.63-4.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -44.49% | -117.92% | -135.74% | -108.08% | -55.97% |
| Total Depreciation and Amortization | 28.73% | 30.88% | 20.17% | 15.45% | 9.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 205.28% | 876.96% | 2,346.72% | 2,788.57% | 2,088.27% |
| Change in Net Operating Assets | -231.60% | 38.81% | -2,743.37% | -332.45% | 484.57% |
| Cash from Operations | -6.02% | 15.28% | -15.15% | -21.57% | 7.61% |
| Capital Expenditure | -44.44% | 91.10% | 89.94% | 89.94% | 90.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -44.44% | 91.10% | 89.94% | 89.94% | 90.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 30.37% | 114.73% | 40.07% | 51.88% | 265.52% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -783.53% | -1,548.84% | -1,336.07% | -613.65% | -78.26% |
| Cash from Financing | -6.06% | 62.05% | -21.27% | 3.32% | 285.62% |
| Foreign Exchange rate Adjustments | -242.07% | -162.33% | 255.41% | 712.50% | 811.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.03% | 90.41% | -36.98% | -3.53% | 1,076.26% |